Welcome to our dedicated page for Telix Pharmaceuticals ADR news (Ticker: TLX), a resource for investors and traders seeking the latest updates and insights on Telix Pharmaceuticals ADR stock.
Telix Pharmaceuticals Limited (TLX) delivers targeted radiopharmaceutical solutions for cancer diagnosis and therapy. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives shaping precision oncology.
Access real-time announcements covering therapeutic developments, partnership agreements, and financial disclosures. Our curated repository ensures efficient tracking of TLX's progress in radioligand therapy and diagnostic imaging innovations, particularly in prostate cancer management.
Key updates include FDA submission statuses, trial phase results, and manufacturing expansions. The content supports informed analysis of Telix's market position without speculative commentary, maintaining compliance with financial reporting standards.
Bookmark this page for streamlined access to primary-source materials and objective reporting on TLX's contributions to nuclear medicine. Regular updates reflect the company's commitment to transforming cancer care through radiopharmaceutical science.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has announced an upcoming Investor Day scheduled for June 11, 2025, in New York City. The event will run from 8:30 AM to 12:00 PM ET and will focus on growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.
Key presenters will include CEO Dr. Christian Behrenbruch, CMO Dr. David N. Cade, CEO Therapeutics Richard Valeix, and CEO Precision Medicine Kevin Richardson. Key Opinion Leaders will also share insights on Telix's theranostic candidates. The event is exclusively for qualified institutional investors and analysts, with advance registration required via email.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has published promising results for its FAP-targeting therapy candidate TLX400 in the Thyroid journal. The study, involving 73 heavily pre-treated patients with radioiodine-resistant (RAI-R) thyroid cancer, demonstrated encouraging efficacy with median progression-free survival of 29 months and overall survival of 32 months.
The treatment showed a 50% partial response rate with manageable adverse events, primarily hematotoxicity. TLX400's novel structure enables prolonged tumor retention while minimizing off-target uptake, potentially offering advantages over current tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, which can have significant side effects.
Telix Pharmaceuticals has received marketing authorization in France for Illuccix, its prostate cancer PET imaging agent. The approval by ANSM enables French healthcare facilities to access this PSMA-PET imaging technology for prostate cancer detection and management.
The approval covers three key clinical applications:
- Primary staging of high-risk prostate cancer patients
- Detection of recurrent cancer in patients with rising PSA levels
- Identification of patients suitable for PSMA-targeted therapy
Telix has partnered with IRE ELiT for marketing and promotion in France, where prostate cancer affects over 57,000 new cases annually. The technology offers superior accuracy compared to conventional imaging methods and allows on-site preparation of PSMA-PET scans, improving accessibility and reducing diagnosis delays.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) reported strong Q1 2025 performance with unaudited revenue of $186 million, up 62% year-over-year and 31% quarter-over-quarter. This includes:
- $151 million from global Illuccix® sales (35% YOY increase)
- $33 million from RLS Radiopharmacies acquisition
The company reaffirmed FY 2025 revenue guidance of $770-800 million. Key developments include:
- FDA approval of Gozellix®, a next-generation PSMA-PET imaging agent
- Positive preliminary results from IPAX-Linz Phase 2 trial for brain cancer therapy
- FDA acceptance of TLX250-CDx BLA with Priority Review
- GMP accreditation for TMS Brussels South facility
The company continues to expand globally with Illuccix® receiving approvals in multiple European markets, UK, and Brazil.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has announced promising preliminary results from its Phase 2 IPAX-Linz study of TLX101 therapy for recurrent high-grade glioma. The study, combining TLX101 with external beam radiation therapy (EBRT), demonstrated a median overall survival of 12.4 months from treatment initiation, or 32.2 months from initial diagnosis.
The trial included eight patients, with treatment well-tolerated and no serious adverse events reported. Five patients had MGMT unmethylated tumors, typically associated with poor prognosis. The results corroborated the positive efficacy signal from the earlier IPAX-1 study, which showed 13 months median survival from treatment.
Telix is advancing its TLX101 development program with ongoing IPAX-2 study in front-line glioblastoma. The company has submitted for ethics approval a registration-enabling study, planning to begin patient enrollment at Australian sites in H2 2025, with U.S. sites expansion following an IND application in H1 2025.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has selected Cardinal Health (NYSE: CAH) as a commercial radiopharmaceutical distributor for Gozellix®, its FDA-approved next-generation PSMA-PET imaging agent for prostate cancer in the United States.
Cardinal Health will deploy Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology for standardized, high-efficiency production of gallium-68 used with Gozellix®. The distribution agreement enables multi-Curie local production and broader availability across U.S. locations, with commercial launch planned for H1 2025.
Cardinal Health will serve as a strategic radiopharmacy distributor alongside Telix's in-house radiopharmacy network, expanding their existing partnership which includes distribution of Illuccix® and Zircaix®.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has appointed Dr. Paul Schaffer as its new Chief Technology Officer (CTO), effective April 07, 2025. Dr. Schaffer joins from ARTMS Inc., where he served as CTO for seven years, and TRIUMF, Canada's particle accelerator research centre, where he was Director of Life Science since 2012.
In his new Vancouver-based role, Dr. Schaffer will oversee Telix's technological advancement in radiopharmaceutical research, development, and clinical applications. His responsibilities will encompass chemistry, physics, artificial intelligence, dosimetry, and data analytics, working alongside Chief Scientist Dr. Michael Wheatcroft's team.
Dr. Schaffer is notably recognized for developing the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was later acquired by Telix in 2024, and for transforming TRIUMF's Life Sciences program, including the design of a multi-cyclotron radiochemistry facility.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker brings over 30 years of global corporate experience in pharmaceutical, biotech, and specialty pharmaceutical sectors, including clinical research and manufacturing organizations.
Currently serving as a Non-Executive Director at Icon PLC (NASDAQ: ICLR) and Chair at QurAlis , Whitaker's most recent executive role was as Chair and CEO of Aerami Therapeutics Holdings. Her career includes senior leadership positions at GlaxoSmithKline, Sanofi, and Bausch Health. She holds a Bachelor of Science in Chemistry and Business from the University of North Alabama.
FAQ
What is the current stock price of Telix Pharmaceuticals ADR (TLX)?
What is the market cap of Telix Pharmaceuticals ADR (TLX)?
